» Articles » PMID: 19947854

Immunogenicity of Toxins During Staphylococcus Aureus Infection

Abstract

Background: Toxins are important Staphylococcus aureus virulence factors, but little is known about their immunogenicity during infection. Here, additional insight is generated.

Methods: Serum samples from 206 S. aureus-infected patients and 201 hospital-admitted control subjects were analyzed for immunoglobulin (Ig) G binding to 20 toxins, using flow-cytometry based technology. Antibody levels were associated with polymerase chain reaction-defined presence of toxin genes in homologous S. aureus isolates.

Results: IgG levels directed to exfoliative toxin (ET) A, ETB, gamma hemolysin B (HlgB), leukocidin (Luk) D, LukE, LukS, staphylococcal enterotoxin (SE) A, SEE, SEH, SEI, and SElM were higher in S. aureus-infected patients than in control subjects (P < .05). Furthermore, in the S. aureus-infected patient group, IgG levels were higher if genes encoding ETA, ETB, SEA, SEC, SEH, SElQ, toxic shock syndrome toxin-1 (TSST-1), or Panton-Valentine leukocidin (PVL) were present in the infectious isolate (P< .05). Levels of anti-SEA IgG increased during infections with sea-positive (median fluorescence intensity from 11,555 to 12,388; P<.05) but not sea-negative strains. In addition, anti-LukS IgG levels increased during skin and soft-tissue infections with luk-PV-positive (median fluorescence intensity from 15,231 to 15,911; P<.05) but not luk-PV-negative strains. Bacteremia was associated with sea (odds ratio, 3.4; 95% confidence interval, 1.2-10.0) and tst (odds ratio, 5.7; 95% confidence interval, 1.6-20.8). Skin and soft-tissue infections and bone and joint infections were associated with luk-PV (odds ratio, 2.5; 95% confidence interval, 1.2-5.2).

Conclusions: Many toxins are expressed in vivo and recognized by the immune system during staphylococcal infections, suggesting their involvement in S. aureus pathogenesis.

Citing Articles

Toxin exposure and HLA alleles determine serum antibody binding to toxic shock syndrome toxin 1 (TSST-1) of .

Weiss S, Holtfreter S, Meyer T, Schmiedeke F, Cammann C, Dorr M Front Immunol. 2023; 14:1229562.

PMID: 37731490 PMC: 10507260. DOI: 10.3389/fimmu.2023.1229562.


Whole-genome sequencing to explore nosocomial transmission and virulence in neonatal methicillin-susceptible Staphylococcus aureus bacteremia.

Slingerland B, Vos M, Bras W, Kornelisse R, De Coninck D, van Belkum A Antimicrob Resist Infect Control. 2020; 9(1):39.

PMID: 32087747 PMC: 7036242. DOI: 10.1186/s13756-020-0699-8.


CASSETTE-clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: study protocol for a randomised controlled trial.

Dotel R, Tong S, Bowen A, Nelson J, OSullivan M, Campbell A Trials. 2019; 20(1):353.

PMID: 31196132 PMC: 6567404. DOI: 10.1186/s13063-019-3452-y.


Comparison of livestock-associated and community-associated Staphylococcus aureus pathogenicity in a mouse model of skin and soft tissue infection.

Randad P, Dillen C, Ortines R, Mohr D, Aziz M, Price L Sci Rep. 2019; 9(1):6774.

PMID: 31043631 PMC: 6494861. DOI: 10.1038/s41598-019-42919-y.


Carriage of from canine otitis externa: antimicrobial resistance profiles and virulence factors associated with skin infection.

Lee G, Lee H, Hwang S, Hong J, Lyoo K, Yang S J Vet Sci. 2019; 20(2):e6.

PMID: 30944529 PMC: 6441802. DOI: 10.4142/jvs.2019.20.e6.